VRNA (Verona Pharma PLC) Company Future Sales Volume

Official company branding of Verona Pharma plc (VRNA)

The expected sales volume of Verona Pharma plc (VRNA) demonstrates an accumulation phase, with the parameter stabilizing at 0.22. The business model is based on the full outsourcing of production and research, which eliminates major capital expenditures. Management must now establish a distribution network for its blockbuster, creating a unique niche in lung therapy without pressure from generics.

VRNA - Verona Pharma plc Company Expected Sales Volume over the range 07/04/2022 - 10/18/2025

Summary analytical data breakdowns for Verona Pharma Inc. (VRNA)

- stock value and consensus price forecast:
Summary company analytics:veronapharma.com
Signature product of Verona Pharma Corp

For fundamental asset screening, this indicator serves as a leading filter, allowing for the identification of undervalued companies prior to the publication of official reports. By analyzing the company's projected future revenue, an investor assesses current market demand in real time, which for Verona Pharma plc (VRNA) signifies stable commercialization potential for drugs in the protected US and European markets, shielded from geopolitical risks.

Analysis of competing companies

Projected Sales Volume HLN|KVUE (Kenvue Inc) - Company Future Revenue|Company Projected Revenue Jyong Biotech MENS|Ligand Pharma - Company Projected Revenue|AMRX - Company Projected Revenue|Company Expected Sales Volume perrigo.com|ALVO (Alvotech SA) - Company Future Sales Volume|Company Sales Forecast Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Projected Sales Volume|ANIP: Company Future Revenue|Company Projected Revenue Afrezza (MNKD)|Projected Sales Volume amphastar.com (AMPH)|Projected Sales Volume PCRX (pacira.com)|Company Future Revenue SPRY|Theravance Biopharma Inc - Projected Sales Volume|Company Future Sales Aquestive Therapeutics AQST|SCPH: Projected Sales Volume|Company Future Sales Volume Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Projected Sales Volume|SXTC (China SXT Pharmaceuticals, Inc.) - Company Projected Revenue Volume|Company Projected Revenue eupraxiapharma.com (EPRX)|Company Projected Revenue Volume BHST|Company Projected Revenue eXoZymes EXOZ|Company Future Revenue ORMP|ENTX - Company Projected Revenue|HYFT: Company Projected Revenue|ABVC BioPharma, Inc (ABVC) - Company Projected Revenue|Cumberland Pharma - Company Future Revenue|QNTM (Quantum BioPharma Corp) - Projected Sales Volume|FibroGen, Inc. - Company Expected Revenue|Projected Sales Volume TELO|Company Future Sales Rani Therapeutics Holdings, Inc.|Company Projected Revenue Synergy CHC Corp. SNYR|Projected Sales Volume rallybio.com RLYB|Lexaria Bioscience Corp. - Projected Sales Volume|PULM: Company Projected Revenue|PTHL (ftzy.com.cn) - Company Future Sales Volume|APM: Company Projected Revenue Volume|LYRA (Lyra Therapeutics Inc) - Projected Sales Volume|Company Revenue Forecast IBO (Impact BioMedical)|Company Future Sales Volume TNFA (TNF Pharmaceuticals)|Projected Sales Volume cbdMD Corp (YCBD)|Projected Sales Volume PRFX (PainReform)|Company Future Sales Auris Medical (CYTO)|LIPO - Company Projected Revenue|Optinose (OPTN) - Company Future Sales Volume|Pieris (PIRS) - Company Projected Revenue|Company Expected Revenue PROC (Procaps Group S.A.)|Company Future Sales Volume PTPI|QLI: Company Future Revenue|Company Projected Revenue acelyrin.com (SLRN)|TFFP (TFF Pharma) - Company Future Revenue